Literature DB >> 31945147

Rapid and accurate Bayesian diagnosis of heparin-induced thrombocytopenia.

Matteo Marchetti1, Stefano Barelli1, Maxime G Zermatten1, Fanny Monnin-Respen1, Elena Matthey-Guirao1, Nicole Nicolas1, Francisco Gomez1, Matthew Goodyer2, Christiane Gerschheimer1, Lorenzo Alberio1.   

Abstract

Prompt diagnostic evaluation of suspected heparin-induced thrombocytopenia (HIT) is critical for guiding initial patient management. We assessed the performance of 3 immunoassays detecting anti-platelet factor 4 (PF4)/heparin antibodies, derived a diagnostic algorithm with a short analytical turnaround time (TAT), and prospectively validated the algorithm. Plasma samples were analyzed by Zymutest-HIA-IgG, HemosIL-AcuStar-HIT-IgG, and ID-H/PF4-PaGIA in retrospective (n = 221) and prospective (n = 305) derivation cohorts. We calculated likelihood ratios of result intervals and cutoff values with 100% negative (NPV) and positive (PPV) predictive values for a positive gold standard functional assay (heparin-induced platelet activation [HIPA]). A diagnostic algorithm was established based on the Bayesian combination of pretest probability and likelihood ratios of first- and second-line immunoassays. Cutoffs with 100% PPV for positive HIPA were >3.0 U/mL (HemosIL-AcuStar-HIT-IgG) and titer ≥16 (ID-H/PF4-PaGIA); cutoffs with 100% NPV were <0.13 U/mL and ≤1, respectively. During the prospective validation of the derived algorithm (n = 687), HemosIL-AcuStar-HIT-IgG was used as unique testing in 566 (82.4%) of 687 cases (analytical TAT, 30 minutes). In 121 (17.6%) of 687 unresolved cases, ID-H/PF4-PaGIA was used as second-line testing (additional TAT, 30 minutes). The algorithm accurately predicted HIT in 51 (7.4%) of 687 patients and excluded it in 604 (87.9%) of 687 patients, leaving only 20 (2.9%) cases unresolved. We also identified 12 (1.7%) of 687 positive predictions not confirmed by HIPA: 10 patients with probable HIT despite negative HIPA and 2 possible false-positive algorithm predictions. The combination of pretest probability with first- and second-line immunoassays for anti-PF4/heparin antibodies is accurate for ruling in or out HIT in ≥95% of cases within 60 minutes. This diagnostic approach improves initial management of patients with suspected HIT.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31945147     DOI: 10.1182/blood.2019002845

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Diagnosing HIT: the need for speed.

Authors:  Adam Cuker; Douglas B Cines
Journal:  Blood       Date:  2020-04-02       Impact factor: 25.476

2.  Combination of two complementary automated rapid assays for diagnosis of heparin-induced thrombocytopenia (HIT).

Authors:  Theodore E Warkentin; Jo-Ann I Sheppard; James W Smith; Na Li; Jane C Moore; Donald M Arnold; Ishac Nazy
Journal:  J Thromb Haemost       Date:  2020-04-27       Impact factor: 5.824

Review 3.  Detection of Platelet-Activating Antibodies Associated with Heparin-Induced Thrombocytopenia.

Authors:  Brigitte Tardy; Thomas Lecompte; François Mullier; Caroline Vayne; Claire Pouplard
Journal:  J Clin Med       Date:  2020-04-24       Impact factor: 4.241

Review 4.  Heparin-Induced Thrombocytopenia: A Review of New Concepts in Pathogenesis, Diagnosis, and Management.

Authors:  Matteo Marchetti; Maxime G Zermatten; Debora Bertaggia Calderara; Alessandro Aliotta; Lorenzo Alberio
Journal:  J Clin Med       Date:  2021-02-10       Impact factor: 4.241

Review 5.  Platelet factor 4 polyanion immune complexes: heparin induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia.

Authors:  Payel Datta; Fuming Zhang; Jonathan S Dordick; Robert J Linhardt
Journal:  Thromb J       Date:  2021-09-15

6.  Measurement of procoagulant platelets provides mechanistic insight and diagnostic potential in heparin-induced thrombocytopenia.

Authors:  Christine S M Lee; Maria V Selvadurai; Leonardo Pasalic; James Yeung; Maria Konda; Geoffrey W Kershaw; Emmanuel J Favaloro; Vivien M Chen
Journal:  J Thromb Haemost       Date:  2022-02-07       Impact factor: 16.036

7.  Managing argatroban in heparin-induced thrombocytopenia: A retrospective analysis of 729 treatment days in 32 patients with confirmed heparin-induced thrombocytopenia.

Authors:  Matteo Marchetti; Stefano Barelli; Tobias Gleich; Francisco J Gomez; Matthew Goodyer; Francesco Grandoni; Lorenzo Alberio
Journal:  Br J Haematol       Date:  2022-03-31       Impact factor: 8.615

Review 8.  Challenges in Detecting Clinically Relevant Heparin-Induced Thrombocytopenia Antibodies.

Authors:  Theodore E Warkentin
Journal:  Hamostaseologie       Date:  2020-10-22       Impact factor: 1.778

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.